

AMENDMENTS TO THE SPECIFICATION

In the amendment filed August 1, 2003, there was an inconsistency between the amended text of the specification as listed in the letter and the amended text as listed on the specification replacement sheet. This letter serves to correct the error of the previously filed specification replacement sheet.

On page 1, lines 8-9 of the specification replacement sheet filed August 1, 2003, please delete: -- filed November 23, 1999 claims benefit to provisional applications 60/121,730, filed February 26, 1999, and 60/146,564, filed July 30, 1999; --

and substitute: -- -- is a Divisional from non-provisional application US Serial No. 09/447,966, filed November 23, 1999, -- --


On page 1 line 11 of the specification replacement sheet filed August 1, 2003, after: -- 08/975,573, issued -- , please insert: -- -- as U.S. 6,265,387 -- --.


A clean version of the Cross-Reference to Related Applications is given below:

This application is a Divisional from non-provisional application US Serial No. 09/447,966, filed November 23, 1999, and is a Continuation-In-Part from nonprovisional application 09/391,260, filed September 7, 1999 which is a Divisional from nonprovisional application 08/975,573, issued as U.S. 6,265,387, which is a Continuation from 08/571,536, filed December 13, 1995, abandoned.

In there are any questions or problems, please contact the undersigned.

Respectfully submitted,


Mark K. Johnson Reg. No. 35,909
Mirus Corporation
505 South Rosa Road
Madison, WI 53719
608-238-4400



[REPLACEMENT SHEET]

INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID

CROSS-REFERENCE TO RELATED APPLICATIONS

This application ~~filed November 23, 1999 claims benefit to provisional applications~~
5 ~~60/121,730, filed February 26, 1999, and 60/146,564, filed July 30, 1999; is a Divisional~~
~~from non-provisional application US Serial No. 09/447,966, filed November 23, 1999, and is~~
a Continuation-In-Part from nonprovisional application 09/391,260, filed September 7, 1999
which is a Divisional from nonprovisional application 08/975,573, issued as U.S. 6,265,387,
which is a Continuation from 08/571,536, filed December 13, 1995, abandoned.

10

FEDERALLY SPONSORED RESEARCH

N/A

FIELD OF THE INVENTION

15 The invention relates to compounds and methods for use in biologic systems. More
particularly, processes that transfer nucleic acids into cells are provided. Nucleic acids in the
form of naked DNA or a nucleic acid combined with another compound are delivered to
cells.

20

BACKGROUND

Biotechnology includes the delivery of a genetic information to a cell to express an
exogenous nucleotide sequence, to inhibit, eliminate, augment, or alter expression of an
endogenous nucleotide sequence, or to express a specific physiological characteristic not
naturally associated with the cell. Polynucleotides may be coded to express a whole or partial
25 protein, or may be anti-sense.

25

A basic challenge for biotechnology and thus its subpart, gene therapy, is to develop
approaches for delivering genetic information to cells of a patient in a way that is efficient
and safe. This problem of "drug delivery," where the genetic material is a drug, is particularly
30 challenging. If genetic material are appropriately delivered they can potentially enhance a
patient's health and, in some instances, lead to a cure. Therefore, a primary focus of gene
therapy is based on strategies for delivering genetic material in the form of nucleic acids.
After delivery strategies are developed they may be sold commercially since they are then
useful for developing drugs.

30